Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC increased its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 6.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 725,621 shares of the company's stock after buying an additional 46,041 shares during the period. Geode Capital Management LLC owned about 1.79% of Keros Therapeutics worth $42,146,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Barclays PLC grew its holdings in Keros Therapeutics by 140.1% during the 3rd quarter. Barclays PLC now owns 60,014 shares of the company's stock worth $3,484,000 after acquiring an additional 35,022 shares in the last quarter. Wellington Management Group LLP purchased a new stake in shares of Keros Therapeutics during the 3rd quarter worth $868,000. Point72 DIFC Ltd grew its stake in shares of Keros Therapeutics by 9.8% during the third quarter. Point72 DIFC Ltd now owns 19,255 shares of the company's stock worth $1,118,000 after purchasing an additional 1,715 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock valued at $55,025,000 after buying an additional 577,220 shares during the last quarter. Finally, Parkman Healthcare Partners LLC raised its stake in Keros Therapeutics by 112.3% in the third quarter. Parkman Healthcare Partners LLC now owns 421,782 shares of the company's stock valued at $24,493,000 after buying an additional 223,155 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on KROS. BTIG Research cut Keros Therapeutics from a "buy" rating to a "neutral" rating in a research report on Thursday, December 12th. TD Cowen downgraded Keros Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, December 12th. Truist Financial cut their price objective on shares of Keros Therapeutics from $100.00 to $43.00 and set a "buy" rating on the stock in a report on Monday. Oppenheimer reduced their price objective on shares of Keros Therapeutics from $102.00 to $63.00 and set an "outperform" rating for the company in a research report on Monday, December 16th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, Keros Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $75.00.

Keros Therapeutics Stock Down 2.4 %

NASDAQ:KROS traded down $0.41 during trading hours on Tuesday, reaching $16.71. 378,972 shares of the company's stock were exchanged, compared to its average volume of 488,891. The firm has a market capitalization of $676.87 million, a price-to-earnings ratio of -3.21 and a beta of 1.20. Keros Therapeutics, Inc. has a 1-year low of $15.67 and a 1-year high of $73.00. The company has a 50-day moving average of $54.10 and a 200 day moving average of $51.40.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million during the quarter. During the same quarter in the prior year, the firm posted ($1.33) earnings per share. The company's revenue for the quarter was up 4750.0% on a year-over-year basis. Research analysts forecast that Keros Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.